- Animalcare continues to expect full year trading to be in line with forecasts although performance is likely to be more second half weighted than in prior years.

Total first half revenue is approximately 10% lower than in the comparable period last time, principally due to a combination of two factors.

The group says the first is the previously described impact of the temporary supply problems with its key product, Buprecare.

But it says good progress has been made on the re-introduction of the Buprecare based products in its range with the initial launch made in France in December and with other key markets to follow in the near future.

Other core veterinary medicine business has held up well. The second factor is the continuing effect of general economic conditions on sales of companion animal identification microchips and related goods and services.

The group says: "Revenue from our pipeline of new veterinary pharmaceuticals continues to grow strongly, with sales of products launched in the previous year showing a 115% increase year on year.

"In addition, our target of launching four new licensed veterinary medicines each financial year was achieved by the end of October 2011, with these new products already starting to make important contributions to the business."

At 8:32am: [LON:ANCR] share price was -11p at 142.5p

Story provided by